The association between renal stone disease and cholesterol gallstones: the easy to believe and not hard to retrieve theory of the metabolic syndrome

References

• Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500–1511
   PubMed Web of Science ®Google Scholar
• Soucie JM, Thun MJ, Coates RJ, McClellan W, Austin H. Demographic and geographic variability of kidney stones in the United States. Kidney Int. 1994;46:893–899
   PubMed Web of Science ®Google Scholar
• Indridason OS, Birgisson S, Edvardsson VO, Sigvaldason H, Sigfusson N, Palsson R. Epidemiology of kidney stones in Iceland: a population-based study. Scand J Urol Nephrol. 2006;40:215–220
   PubMed Web of Science ®Google Scholar
• Buchholz NP, Abbas F, Afzal M, Khan R, Rizvi I, Talati J. The prevalence of silent kidney stones – an ultrasonographic screening study. J Pak Med Assoc. 2003;53:24–25
   PubMedGoogle Scholar
• Marschall HU, Einarsson C. Gallstone disease. J Intern Med. 2007;261:529–542
   PubMed Web of Science ®Google Scholar
• Domingos F, Serra A. Nephrolithiasis is associated with an increased prevalence of cardiovascular disease. Nephrol Dial Transplant. 2011;26:864–868
   PubMed Web of Science ®Google Scholar
• Shaffer EA. Gallstone disease: epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol. 2006;20:981–996
   PubMed Web of Science ®Google Scholar
• Ahmed MH, Hamad MA, Routh C, Connolly V. Statins as potential treatment for cholesterol gallstones: an attempt to understand the underlying mechanism of actions. Expert Opin Pharmacother. 2011;12:2673–2681
   PubMed Web of Science ®Google Scholar
• Saucier NA, Sinha MK, Liang KV, et al. Risk factors for CKD in persons with kidney stones: a case-control study in Olmsted County, Minnesota. Am J Kidney Dis. 2010;55:61–68
   PubMed Web of Science ®Google Scholar
• Ruhl CE, Everhart JE. Gallstone disease is associated with increased mortality in the United States. Gastroenterology. 2011;140:508–516
   PubMed Web of Science ®Google Scholar
• Mendez-Sanchez N, Bahena-Aponte J, Chavez-Tapia NC, et al. Strong association between gallstones and cardiovascular disease. Am J Gastroenterol. 2005;100:827–830
   PubMed Web of Science ®Google Scholar
• Mendez-Sanchez N, Zamora-Valdes D, Flores-Rangel JA, et al. Gallstones are associated with carotid atherosclerosis. Liver Int. 2008;28:402–406
   PubMed Web of Science ®Google Scholar
• Rule AD, Roger VL, Melton III LJ, et al. Kidney stones associate with increased risk for myocardial infarction. J Am Soc Nephrol. 2010;21:1641–1644
   PubMed Web of Science ®Google Scholar
• Taylor EN, Chan AT, Giovannucci EL, Curhan GC. Cholelithiasis and the risk of nephrolithiasis. J Urol. 2011;186:1882–1887
   PubMedGoogle Scholar
• Akoudad S, Szklo M, McAdams MA, et al. Correlates of kidney stone disease differ by race in a multi-ethnic middle-aged population: the ARIC study. Prev Med. 2010;51:416–420
   PubMed Web of Science ®Google Scholar
• Li CH, Sung FC, Wang YC, Lin D, Kao CH. Gallstones increase the risk of developing renal stones: a nationwide population-based retrospective cohort study. QJM. 2014 Jan 22. [Epub ahead of print]. doi: 10.1093/qjmed/hcu017
   Google Scholar
• Lai SW, Liao KF, Lai HC, Chou CY, Cheng KC, Lai YM. The prevalence of gallbladder stones is higher among patients with chronic kidney disease in Taiwan. Medicine (Baltimore). 2009;88:46–51
   PubMed Web of Science ®Google Scholar
• Kazama JJ, Kazama S, Koda R, Yamamoto S, Narita I, Gejyo F. The risk of gallbladder stone formation is increased in patients with predialysis chronic kidney disease but not those undergoing chronic hemodialysis therapy. Nephron Clin Pract. 2009;111:c167–c172
   PubMedGoogle Scholar
• Park SH, Hahm JS, Seong SS, et al. Incidence of gallbladder stones in renal transplant recipients. Korean J Gastroenterol. 2004;44:42–46
   PubMedGoogle Scholar
• Kim SS, Lee JG, Kim DW, et al. Insulin resistance as a risk factor for gallbladder stone formation in Korean postmenopausal women. Korean J Intern Med. 2011;26:285–293
   PubMedGoogle Scholar
• Shebl FM, Andreotti G, Meyer TE, et al. Metabolic syndrome and insulin resistance in relation to biliary tract cancer and stone risks: a population-based study in Shanghai, China. Br J Cancer. 2011;105:1424–1429
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4:1565–1574
   PubMed Web of Science ®Google Scholar
• Ahmed MH, Byrne CD. Metabolic syndrome, diabetes & CHD risk. In: Packard CJ, ed. The Year in Lipid Disorders. Oxford UK: Clinical Publishing; 2007:3–26
   Google Scholar
• Ahmed MH, Khalil A, Osman MM. Nitric oxide as treatment for an emerging epidemic of obesity-related glomerulopathy. Diabetes Res Clin Pract. 2006;74:207–208
   PubMed Web of Science ®Google Scholar
• Wesson DE, Kurtzman NA, Frommer JP. Massive obesity and nephrotic proteinuria with a normal renal biopsy. Nephron. 1985;40:235–237
   PubMed Web of Science ®Google Scholar
• Najeeb Q, Masood I, Bhaskar N, et al. Effect of BMI and urinary pH on urolithiasis and its composition. Saudi J Kidney Dis Transpl. 2013;24:60–66
   PubMedGoogle Scholar
• Allard CB, Shuster A, Pinthus JH, et al. Obesometric factors associated with increased skin-to-stone distances in renal stone patients. Can J Urol. 2012;19:6554–6559
   PubMedGoogle Scholar
• Arrabal-Polo MA, Arrabal-Martin M, Garrido-Gomez J. Calcium renal lithiasis: metabolic diagnosis and medical treatment. Sao Paulo Med J. 2013;131:46–53
   PubMedGoogle Scholar
• Abu Ghazaleh LA, Budair Z. The relation between stone disease and obesity in Jordan. Saudi J Kidney Dis Transplant. 2013;24:610–614
   PubMedGoogle Scholar
• Semins MJ, Shore AD, Makary MA, Magnuson T, Johns R, Matlaga BR. The association of increasing body mass index and kidney stone disease. J Urol. 2010;183:571–575
   PubMed Web of Science ®Google Scholar
• Chen LY, Qiao QH, Zhang SC, Chen YH, Chao GQ, Fang LZ. Metabolic syndrome and gallstone disease. World J Gastroenterol. 2012;18:4215–4220
   PubMed Web of Science ®Google Scholar
• Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr. 2004;80:38–44
   PubMed Web of Science ®Google Scholar
• West B, Luke A, Durazo-Arvizu RA, Cao G, Shoham D, Kramer H. Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988–1994. Am J Kidney Dis. 2008;51:741–747
   PubMed Web of Science ®Google Scholar
• Jeong IG, Kang T, Bang JK, et al. Association between metabolic syndrome and the presence of kidney stones in a screened population. Am J Kidney Dis. 2011;58:383–388
   PubMed Web of Science ®Google Scholar
• Ata N, Kucukazman M, Yavuz B, et al. The metabolic syndrome is associated with complicated gallstone disease. Can J Gastroenterol. 2011;25:274–276
   PubMed Web of Science ®Google Scholar
• Weikert C, Weikert S, Schulze MB, et al. Presence of gallstones or kidney stones and risk of type 2 diabetes. Am J Epidemiol. 2010;171:447–454
   PubMed Web of Science ®Google Scholar
• Kim JM, Lee HL, Moon W, et al. Association between insulin, insulin resistance, and gallstone disease in Korean general population. Korean J Gastroenterol. 2007;50:183–187
   PubMedGoogle Scholar
• Nervi F, Miquel JF, Alvarez M, et al. Gallbladder disease is associated with insulin resistance in a high risk Hispanic population. J Hepatol. 2006;45:299–305
   PubMed Web of Science ®Google Scholar
• Chang Y, Sung E, Ryu S, Park YW, Jang YM, Park M. Insulin resistance is associated with gallstones even in non-obese, non-diabetic Korean men. J Korean Med Sci. 2008;23:644–650
   PubMed Web of Science ®Google Scholar
• Nakeeb A, Comuzzie AG, Al-Azzawi H, Sonnenberg GE, Kissebah AH, Pitt HA. Insulin resistance causes human gallbladder dysmotility. J Gastrointest Surg. 2006;10:940–948
   PubMed Web of Science ®Google Scholar
• Maalouf NM, Sakhaee K, Parks JH, Coe FL, ms-Huet B, Pak CY. Association of urinary pH with body weight in nephrolithiasis. Kidney Int. 2004;65:1422–1425
   PubMed Web of Science ®Google Scholar
• Maalouf NM, Cameron MA, Moe OW, ms-Huet B, Sakhaee K. Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol. 2007;2:883–888
   PubMed Web of Science ®Google Scholar
• Ahmed MH, Byrne CD. Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events. Diabetes Obes Metab. 2010;12:958–966
   PubMed Web of Science ®Google Scholar
• Ahmed MH. Orlistat and calcium oxalate crystalluria: an association that needs consideration. Ren Fail. 2010;32:1019–1021
   PubMed Web of Science ®Google Scholar
• Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005;68:1230–1235
   PubMed Web of Science ®Google Scholar
• Okamoto M, Kohjimoto Y, Iba A, Saji F, Hara I, Shigematsu T. Calcium oxalate crystal deposition in metabolic syndrome model rat kidneys. Int J Urol. 2010;17:996–1003
   PubMed Web of Science ®Google Scholar
• Maalouf NM, Cameron MA, Moe OW, ms-Huet B, Sakhaee K. Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol. 2007;2:883–888
   PubMed Web of Science ®Google Scholar
• Abate N, Chandalia M, Cabo-Chan Jr AV, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004;65:386–392
   PubMed Web of Science ®Google Scholar
• Sakhaee K, ms-Huet B, Moe OW, Pak CY. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int. 2002;62:971–979
   PubMed Web of Science ®Google Scholar
• Eisner BH, Porten SP, Bechis SK, Stoller ML. Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers. J Urol. 2010;183:2244–2248
   PubMed Web of Science ®Google Scholar
• Daudon M, Lacour B, Jungers P. High prevalence of uric acid calculi in diabetic stone formers. Nephrol Dial Transplant. 2005;20:468–469
   PubMed Web of Science ®Google Scholar
• Daudon M, Traxer O, Conort P, Lacour B, Jungers P. Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol. 2006;17:2026–2033
   PubMed Web of Science ®Google Scholar
• Vollans SR, Sehjal R, Forster JA, Rogawski KM. Emphysematous pyelonephritis in type II diabetes: a case report of an undiagnosed ureteric colic. Cases J. 2008;1:192. doi: 10.1186/1757-1626-1-192
   PubMedGoogle Scholar
• Chan AC, Rohan MJ, Hamid A, Azam A. Emphysematous pyelonephritis in a diabetic patient with pelvic-ureteric stone. Med J Malaysia. 2007;62:166–167
   PubMedGoogle Scholar
• Chung SD, Liao CH, Sun HD, Wen WC. Emphysematous pyelonephritis with acute renal failure. Urology. 2008;72:521–522
   PubMed Web of Science ®Google Scholar
• Chapman BA, Wilson IR, Frampton CM, et al. Prevalence of gallbladder disease in diabetes mellitus. Dig Dis Sci. 1996;41:2222–2228
   PubMed Web of Science ®Google Scholar
• Pagliarulo M, Fornari F, Fraquelli M, et al. Gallstone disease and related risk factors in a large cohort of diabetic patients. Dig Liver Dis. 2004;36:130–134
   PubMedGoogle Scholar
• Elmehdawi R, Elmajberi S, Behieh A, Elramli A. Prevalence of gall bladder stones among type 2 diabetic patients in Benghazi Libya: a case-control study. Libyan J Med. 2009;4:27–30
   PubMed Web of Science ®Google Scholar
• Liu CM, Tung TH, Liu JH, Lee WL, Chou P. A community-based epidemiologic study on gallstone disease among type 2 diabetics in Kinmen, Taiwan. Dig Dis. 2004;22:87–91
   PubMed Web of Science ®Google Scholar
• Al-Bayati S, Kodayer S. Gallstones in a group of Iraqi patients with type 2 diabetes mellitus. Saudi Med J. 2012;33:412–417
   PubMedGoogle Scholar
• Serrano PE, Khuder SA, Fath JJ. Obesity as a risk factor for nosocomial infections in trauma patients. J Am Coll Surg. 2010;211:61–67
   PubMed Web of Science ®Google Scholar
• Bochicchio GV, Joshi M, Shih D, Bochicchio K, Tracy K, Scalea TM. Reclassification of urinary tract infections in critically ill trauma patients: a time-dependent analysis. Surg Infect (Larchmt). 2003;4:379–385
   PubMedGoogle Scholar
• Maurer KJ, Carey MC, Fox JG. Roles of infection, inflammation, and the immune system in cholesterol gallstone formation. Gastroenterology. 2009;136:425–440
   PubMed Web of Science ®Google Scholar
• Ahmed MH, Byrne CD. Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today. 2007;12:740–747
   PubMed Web of Science ®Google Scholar
• Ahmed MH, Abu EO, Byrne CD. Non-Alcoholic Fatty Liver Disease (NAFLD): new challenge for general practitioners and important burden for health authorities? Prim Care Diabetes. 2010;4:129–137
   PubMedGoogle Scholar
• Semins MJ, Shore AD, Makary MA, Weiner J, Matlaga BR. The impact of obesity on urinary tract infection risk. Urology. 2012;79:266–269
   PubMed Web of Science ®Google Scholar
• Haidinger G, Temml C, Schatzl G, et al. Risk factors for lower urinary tract symptoms in elderly men. For the Prostate Study Group of the Austrian Society of Urology. Eur Urol. 2000;37:413–420
   PubMed Web of Science ®Google Scholar
• Magan AA, Khalil AA, Ahmed MH. Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists. World J Gastroenterol. 2010;16:5139–5147
   PubMedGoogle Scholar
• Seager CM, Srinivas TR, Flechner SM. Development of nephrolithiasis in a renal transplant patient during treatment with Cinacalcet. Ann Transplant. 2013;18:31–35
   PubMedGoogle Scholar
• Badalamenti S, DeFazio C, Castelnovo C, et al. High prevalence of silent gallstone disease in dialysis patients. Nephron. 1994;66(2):225–227
   PubMedGoogle Scholar